AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23706959 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measurement using EuroQol EQ‐5D at day 28
Number of subjects: 0
Study 23706959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost estimation associated with hospitalization for AUGIB in the UK
Number of subjects: 0
Study 20650654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal hemodialysis (NHD)
Number of subjects: 51
Study 20650654 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (HD)
Number of subjects: 51
Study 18988663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing education consisting of small group sessions and an educational outreach session
Number of subjects: 19
Study 18988663 — intervention group
Group type: COMPARATOR
Intervention: No further education (control group)
Number of subjects: 19
Study 18988663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing education
Number of subjects: 19
Study 16911911 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 18
Study 16911911 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/day
Number of subjects: 18
Study 15224295 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-radiation therapy (gamma-RT)
Number of subjects: 130
Study 15224295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 11282761 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (0.5 g/10 kg body weight)
Number of subjects: 19
Study 11282761 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (1.5 g/10 kg body weight/d)
Number of subjects: 19
Study 11282761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9164878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-A group (AMI patients with low atrial contraction flow velocity)
Number of subjects: 206
Study 7815238 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose hydrolyzed milk formula
Number of subjects: 135
Study 7815238 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free corn syrup-based milk formula
Number of subjects: 135
Study 7815238 — intervention group
Group type: COMPARATOR
Intervention: Standard lactose-containing formula
Number of subjects: 135
Study 3174786 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (2.7% delta 9‐THC w/w)
Number of subjects: 6
Study 3174786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31295358 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 31295358 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 27773350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation based on GEDI (goal-directed therapy until GEDI reached 800 mL/m2)
Number of subjects: 71
Study 27773350 — intervention group
Group type: COMPARATOR
Intervention: Fluid resuscitation based on central venous pressure (control group)
Number of subjects: 71
Study 25256125 — intervention group
Group type: COMPARATOR
Intervention: Topical hydrocortisone cream 1% (control group)
Number of subjects: 23
Study 25256125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hai's Perianal Support (HPS) toilet seat device (test group)
Number of subjects: 23
Study 22948945 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitin-glucan (CG) 4.5 g/day
Number of subjects: 130
Study 22948945 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitin-glucan (CG) 1.5 g/day
Number of subjects: 130
Study 22948945 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitin-glucan (CG) 1.5 g/day plus olive oil (OO) extract 135 mg/day
Number of subjects: 130
Study 22948945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 22021533 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp imaging (n = 103)
Number of subjects: 208
Study 22021533 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp imaging (n = 105)
Number of subjects: 208
Study 18598379 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 18598379 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16447104 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (ABCD) 7.5 mg/kg (group A)
Number of subjects: 405
Study 16447104 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (ABCD) 10 mg/kg (group B)
Number of subjects: 405
Study 16447104 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (ABCD) 15 mg/kg (group C)
Number of subjects: 405
Study 12903909 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mol/l hydrochloric acid instillation
Number of subjects: 20
Study 12903909 — intervention group
Group type: COMPARATOR
Intervention: saline instillation
Number of subjects: 20
Study 10769855 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam, nalbuphine, and droperidol administered intravenously, along with nitrous oxide and oxygen by nasal mask.
Number of subjects: 153
Study 10769855 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam, nalbuphine, and droperidol administered intravenously.
Number of subjects: 153
Study 9069567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower GIR group (insulin resistance)
Number of subjects: 33
Study 9069567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate GIR group (insulin resistance)
Number of subjects: 33
Study 9069567 — intervention group
Group type: COMPARATOR
Intervention: Highest GIR group (insulin resistance)
Number of subjects: 33
Study 8282507 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolar contrast media
Number of subjects: 24
Study 8282507 — intervention group
Group type: COMPARATOR
Intervention: High-osmolar contrast media
Number of subjects: 24
Study 3321540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline 7.5 mg twice daily
Number of subjects: 9
Study 31955270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandible reconstruction template tool
Number of subjects: 100
Study 30600754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 20 mg nefopam in 100 mL normal saline before spinal anesthesia
Number of subjects: 70
Study 30600754 — intervention group
Group type: COMPARATOR
Intervention: Placebo: intravenous normal saline 100 mL
Number of subjects: 70
Study 27378824 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 182
Study 27378824 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol and Montelukast (SM)
Number of subjects: 182
Study 25753362 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care (StanC) plus an 8-week exercise and education intervention
Number of subjects: 244
Study 25753362 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (StanC)
Number of subjects: 244
Study 22538472 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhering flowable resin composite (Vertise Flow, VF)
Number of subjects: 80
Study 22538472 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching (PAE) with VF
Number of subjects: 80
Study 22538472 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (SE)
Number of subjects: 80
Study 22538472 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse adhesive (E&R)
Number of subjects: 80
Study 22055594 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy (20mg omeprazole bid, 1000mg amoxicillin bid, 500mg clarithromycin bid for 14 days)
Number of subjects: 180
Study 22055594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (20mg omeprazole bid and 1000mg amoxicillin bid for 14 days, 500mg ciprofloxacin bid for the first 7 days, 200mg furazolidone bid for the last 7 days)
Number of subjects: 180
Study 22055594 — intervention group
Group type: COMPARATOR
Intervention: Control group (CrCl >90 mg/dl)
Number of subjects: 180
Study 18434749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 42
Study 18434749 — intervention group
Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 42
Study 17173490 — intervention group
Group type: EXPERIMENTAL
Intervention: Know Your Health (KYH) program (education)
Number of subjects: 347
Study 17173490 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 347
Study 12706405 — intervention group
Group type: EXPERIMENTAL
Intervention: CIV IL-2 (12 mIU/day) for 3 days plus ART
Number of subjects: 81
Study 12706405 — intervention group
Group type: EXPERIMENTAL
Intervention: CIV IL-2 (12 mIU/day) for 4 days plus ART
Number of subjects: 81
Study 12706405 — intervention group
Group type: EXPERIMENTAL
Intervention: CIV IL-2 (12 mIU/day) for 5 days plus ART
Number of subjects: 81
Study 12706405 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 81
Study 11070565 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol combined with amlodipine
Number of subjects: 0
Study 11070565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8833409 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (IFN), 5.0 MU three times a week for one year (n = 48)
Number of subjects: 98
Study 8833409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, n = 50)
Number of subjects: 98
Study 8833409 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (IFN)
Number of subjects: 98
Study 8833409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 98
Study 1329300 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg thrice daily for 1 week
Number of subjects: 95
Study 1329300 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 95
Study 1329300 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic stone formers
Number of subjects: 95
Study 6462980 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 209
Study 6462980 — intervention group
Group type: EXPERIMENTAL
Intervention: Median incision
Number of subjects: 209
Study 6462980 — intervention group
Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 209
Study 31373420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing adaptation (removal of bath or inaccessible shower, replacement with level access shower)
Number of subjects: 26
Study 29251687 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) intervention including interactive student seminar, structured physical activity program focused on RT, lunchtime fitness sessions, and Web-based smartphone apps
Number of subjects: 607
Study 29251687 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 607
Study 24708832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training for 16 weeks, 3 supervised sessions per week
Number of subjects: 100
Study 24708832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention during the 16-week period)
Number of subjects: 100
Study 22522357 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical MMR vaccine
Number of subjects: 26
Study 22522357 — intervention group
Group type: COMPARATOR
Intervention: Excision alone (control)
Number of subjects: 26
Study 20429049 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (GLU) 0.2 U/kg
Number of subjects: 12
Study 20429049 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (ASP) 0.2 U/kg
Number of subjects: 12
Study 18005803 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home early recovery management intervention delivered via Health Buddy device for 6 weeks
Number of subjects: 49
Study 18005803 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 49
Study 16055524 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with AMS at high altitude
Number of subjects: 41
Study 16055524 — intervention group
Group type: COMPARATOR
Intervention: Subjects without AMS at high altitude
Number of subjects: 41
Study 16055524 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with AMS during short-term hypoxia
Number of subjects: 41
Study 12114885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (n = 103)
Number of subjects: 209
Study 12114885 — intervention group
Group type: COMPARATOR
Intervention: No substitution (Control group, n = 106)
Number of subjects: 209
Study 10399787 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 Gy of 6MV X‐rays (radiotherapy)
Number of subjects: 103
Study 10399787 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 103
Study 7580551 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg daily for 12 weeks)
Number of subjects: 195
Study 7580551 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (200 mg daily for 12 weeks)
Number of subjects: 195
Study 2073105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil 15 mg/kg
Number of subjects: 20
Study 2073105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil 30 mg/kg
Number of subjects: 20
Study 2073105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis isomer 15 mg/kg
Number of subjects: 20
Study 2073105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis isomer 30 mg/kg
Number of subjects: 20
Study 2073105 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans isomer 15 mg/kg
Number of subjects: 20
Study 2073105 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans isomer 30 mg/kg
Number of subjects: 20
Study 6974454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammary radiography screening
Number of subjects: 15748
Study 30659782 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 105
Study 30659782 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 105
Study 30659782 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure attachment
Number of subjects: 105
Study 28651599 — intervention group
Group type: EXPERIMENTAL
Intervention: synthetic CT (synCT)
Number of subjects: 11
Study 28651599 — intervention group
Group type: COMPARATOR
Intervention: CT (planCT)
Number of subjects: 11
Study 26295638 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 20
Study 26295638 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mmol/kg gadopentetate dimeglumine
Number of subjects: 20
Study 23404949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 121
Study 23404949 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 121
Study 21247601 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sacral nerve stimulation
Number of subjects: 12
Study 21247601 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nerve evaluation test
Number of subjects: 12
Study 19136088 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary fiber intake
Number of subjects: 336
Study 19136088 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depressive symptoms
Number of subjects: 336
Study 19136088 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urinary tract symptoms
Number of subjects: 336
Study 17785486 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8479
Study 17785486 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8479
Study 17785486 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in Cornell product (continuous variable)
Number of subjects: 8479
Study 17785486 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater-than-median decrease in Cornell product (dichotomous variable)
Number of subjects: 8479
Study 17785486 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment decrease of Cornell product (continuous variable)
Number of subjects: 8479
Study 17785486 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment reduction in Cornell product of 236 mm x msec or more
Number of subjects: 8479
Study 16135349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (IV PCA) with morphine (1.5 mg; lockout interval, 8 min)
Number of subjects: 45
Study 16135349 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve sheath block (FNB)
Number of subjects: 45
Study 16135349 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (EPI)
Number of subjects: 45
Study 12297207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (bean extract)
Number of subjects: 62
Study 12297207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10995137 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide in oxygen
Number of subjects: 34
Study 10995137 — intervention group
Group type: COMPARATOR
Intervention: 40% oxygen in air
Number of subjects: 34
Study 7480615 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education program
Number of subjects: 1709
Study 2312918 — intervention group
Group type: EXPERIMENTAL
Intervention: Group information about the disease
Number of subjects: 48
Study 2312918 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual information about the disease
Number of subjects: 48
Study 2312918 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of the whole information at once
Number of subjects: 48
Study 2312918 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of the information into three parts separated by 15 minutes
Number of subjects: 48
Study 2312918 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall information provided
Number of subjects: 48
Study 533575 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg antipyrine
Number of subjects: 5
Study 533575 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg antipyrine
Number of subjects: 5
Study 533575 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg antipyrine
Number of subjects: 5
Study 31274487 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 114
Study 31274487 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TA)
Number of subjects: 114
Study 31274487 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 114
Study 31274487 — intervention group
Group type: COMPARATOR
Intervention: TA
Number of subjects: 114
Study 31274487 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA and TA
Number of subjects: 114
Study 28488078 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic context presentation of vocabulary
Number of subjects: 64
Study 28488078 — intervention group
Group type: COMPARATOR
Intervention: Explicit definition presentation of vocabulary
Number of subjects: 64
Study 24191873 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma of argon cleaning treatment
Number of subjects: 30
Study 24191873 — intervention group
Group type: COMPARATOR
Intervention: Control (abutment subjected only to usually adopted cleaning protocol by steam)
Number of subjects: 30
Study 23289009 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (daily oral Zn supplements for eight weeks)
Number of subjects: 65
Study 23289009 — intervention group
Group type: COMPARATOR
Intervention: No supplements (control group)
Number of subjects: 65
Study 23289009 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 65
Study 21258242 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane (AM)
Number of subjects: 102
Study 18976257 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA) 800 mg day(-1) for 8 weeks
Number of subjects: 60
Study 18976257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16923843 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' interest in poisoning (81%)
Number of subjects: 105
Study 16923843 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' interest in car crashes (49%)
Number of subjects: 105
Study 16923843 — intervention group
Group type: COMPARATOR
Intervention: Childhood injury risk for poisoning
Number of subjects: 105
Study 16923843 — intervention group
Group type: COMPARATOR
Intervention: Childhood injury risk for fires
Number of subjects: 105
Study 16923843 — intervention group
Group type: COMPARATOR
Intervention: Childhood injury risk for falls
Number of subjects: 105
Study 16923843 — intervention group
Group type: COMPARATOR
Intervention: Childhood injury risk for car crashes
Number of subjects: 105
Study 15124551 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (5-FU-CDDP)
Number of subjects: 222
Study 15124551 — intervention group
Group type: COMPARATOR
Intervention: Concomitant radiotherapy (5FU‐MMC)
Number of subjects: 222
Study 15124551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation of the boost from 15 Gy to 25-25 Gy
Number of subjects: 222
Study 10795929 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin V2 antagonists
Number of subjects: 0
Study 10795929 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (fluid restriction and treatment of underlying disorder)
Number of subjects: 0
Study 8698956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus narrowing using prepackaged foods
Number of subjects: 0
Study 8698956 — intervention group
Group type: COMPARATOR
Intervention: Regular food
Number of subjects: 0
Study 1577025 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (20 mg.day‐1)
Number of subjects: 18
Study 1577025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3831143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg three times daily)
Number of subjects: 30
Study 3831143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3831143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 30
Study 31329991 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% RPS diet
Number of subjects: 600
Study 31329991 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% RPS diet
Number of subjects: 600
Study 31329991 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% and 18% RPS diets
Number of subjects: 600
Study 31329991 — intervention group
Group type: COMPARATOR
Intervention: 0% RPS diet (control)
Number of subjects: 600